Analysts expect Motus GI Holdings Inc (NASDAQ:MOTS) to report $30,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Motus GI’s earnings. The firm is expected to issue its next earnings results on Thursday, November 12th.
According to Zacks, analysts expect that Motus GI will report full year sales of $200,000.00 for the current fiscal year, with estimates ranging from $140,000.00 to $300,000.00. For the next fiscal year, analysts forecast that the company will post sales of $4.24 million, with estimates ranging from $1.88 million to $6.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Motus GI.
Motus GI (NASDAQ:MOTS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. Motus GI had a negative return on equity of 139.08% and a negative net margin of 16,834.35%.
Shares of NASDAQ MOTS remained flat at $$1.02 during trading on Friday. The stock had a trading volume of 84,909 shares, compared to its average volume of 122,629. Motus GI has a 1 year low of $0.46 and a 1 year high of $2.99. The company has a quick ratio of 1.77, a current ratio of 1.90 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $29.53 million, a price-to-earnings ratio of -1.34 and a beta of 2.78. The company has a 50 day simple moving average of $1.09 and a 200 day simple moving average of $1.08.
Motus GI Company Profile
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Recommended Story: Resistance Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.